Global Transthyretin Stabilizer Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Transthyretin Stabilizer Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

According to our (Global Info Research) latest study, the global Transthyretin Stabilizer market size was valued at USD 1522.8 million in 2023 and is forecast to a readjusted size of USD 2382.6 million by 2030 with a CAGR of 6.6% during review period.

Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.

TTR stabilizers work by binding to and stabilizing the TTR protein, preventing it from misfolding and forming amyloid fibrils. By stabilizing the TTR protein, these medications aim to slow down or halt the progression of the disease and potentially alleviate symptoms.

The global transthyretin stabilizer market refers to the market for medications and compounds used in the treatment of transthyretin amyloidosis (ATTR) by stabilizing the transthyretin (TTR) protein. This market encompasses various drugs that have been developed or under development as TTR stabilizers.

Currently, there are several TTR stabilizers that have gained regulatory approval or are in advanced stages of clinical development. The market is primarily driven by the rising prevalence of ATTR, increasing awareness of the disease, and the need for effective treatment options.

One of the key drugs in the market is tafamidis, which is approved in several countries for the treatment of ATTR polyneuropathy. Tafamidis has shown to stabilize TTR and slow disease progression in clinical trials. Other drugs such as diflunisal, AG10, inotersen, and patisiran are also being investigated and have shown promising results in clinical studies.

The market is expected to witness significant growth as more research is conducted on the development of TTR stabilizers and as regulatory approvals are obtained for these drugs in different regions. Additionally, the ongoing efforts to increase disease awareness among healthcare professionals and patients are likely to contribute to the market growth.

Key players in the global transthyretin stabilizer market include pharmaceutical companies such as Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, and Ionis Pharmaceuticals Inc., among others. These companies invest in research and development activities to develop new TTR stabilizers and expand their product portfolios.

Geographically, North America and Europe are leading regions in the market, primarily due to the higher prevalence of ATTR and the presence of established healthcare infrastructure. However, as awareness and diagnosis of ATTR improve in other regions such as Asia Pacific and Latin America, these regions are likely to exhibit significant growth opportunities.

In conclusion, the global transthyretin stabilizer market is expected to grow as more effective treatments are developed and approved for ATTR. The market is driven by the increasing prevalence of the disease and the need for therapies that can stabilize the TTR protein and slow disease progression.

The Global Info Research report includes an overview of the development of the Transthyretin Stabilizer industry chain, the market status of Hospital Pharmacies (Diflunisal, Tafamidis), Retail Pharmacies (Diflunisal, Tafamidis), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Transthyretin Stabilizer.

Regionally, the report analyzes the Transthyretin Stabilizer markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Transthyretin Stabilizer market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Transthyretin Stabilizer market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Transthyretin Stabilizer industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Diflunisal, Tafamidis).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Transthyretin Stabilizer market.

Regional Analysis: The report involves examining the Transthyretin Stabilizer market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Transthyretin Stabilizer market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Transthyretin Stabilizer:

Company Analysis: Report covers individual Transthyretin Stabilizer manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Transthyretin Stabilizer This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacies, Retail Pharmacies).

Technology Analysis: Report covers specific technologies relevant to Transthyretin Stabilizer. It assesses the current state, advancements, and potential future developments in Transthyretin Stabilizer areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Transthyretin Stabilizer market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Transthyretin Stabilizer market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Diflunisal
Tafamidis
Others

Market segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Others

Major players covered
Pfizer Inc.
Merck & Co.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Corino Therapeutics Inc.
Alnylam Pharmaceuticals
Bellus Health Inc.
Ionis Pharmaceuticals, Inc.
Proclara Bioscience
Arturus Therapeutics
Prothena Corporation Plc.

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Transthyretin Stabilizer product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Transthyretin Stabilizer, with price, sales, revenue and global market share of Transthyretin Stabilizer from 2019 to 2024.

Chapter 3, the Transthyretin Stabilizer competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Transthyretin Stabilizer breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Transthyretin Stabilizer market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Transthyretin Stabilizer.

Chapter 14 and 15, to describe Transthyretin Stabilizer sales channel, distributors, customers, research findings and conclusion. Show more